FDA Approves Tazverik for Advanced Epithelioid Sarcoma in Patients Aged 16 Years & Older

On Jan. 23, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Tazverik (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Epithelioid sarcoma is a rare sub-type of soft tissue sarcoma that often occurs in young adults.

Tazverik blocks activity of the EZH2 methyltransferase, which may help keep the cancer cells from growing.

Read FDA announcement.

Posted 1/24/2020